Progression‐free survival · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin probably leads to lower progression‐free survival (PFS) compared with tri‐weekly paclitaxel plus carboplatin (moderate certainty).
1 finding from 1 review
Overall survival (OS) · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin showed no clear difference in overall survival (OS) compared with tri‐weekly paclitaxel plus carboplatin (high certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin showed no clear difference in haematological adverse event: Grade 3/4 neutropenia compared with tri‐weekly paclitaxel plus carboplatin (moderate certainty).
1 finding from 1 review
Grade 3 and 4 hematological adverse events (AE) ‐ anemia · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin leads to higher haematological adverse event: Grade 3/4 anaemia compared with tri‐weekly paclitaxel plus carboplatin (high certainty).
1 finding from 1 review
Neurological adverse event: Grade 3/4 neuropathy, not otherwise specified · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin showed no clear difference in neurological adverse event: Grade 3/4 neuropathy, not otherwise… compared with tri‐weekly paclitaxel plus carboplatin (low certainty).
1 finding from 1 review
Overall Survivalclinical observation · patients with ovarian cancer
Topotecon+Carboplatin+Paclitaxel showed no clear difference in overall Survivalclinical observation compared with carboplatin+Paclitaxel (high certainty).
1 finding from 1 review
Progression‐free survival · patients with ovarian cancer
Topotecon+Carboplatin+Paclitaxel may leads to higher progress free survival compared with carboplatin+Paclitaxel (low certainty).
1 finding from 1 review
Intervention not reported
BEV+IRI (1 RCT, 79 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention leads to higher BEV+IRI (1 RCT, 79 participants) (high certainty).
1 finding from 1 review
Intervention not reported
BEV+VB111 (1 RCT, 128 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention leads to higher BEV+VB111 (1 RCT, 128 participants) (high certainty).
1 finding from 1 review
Intervention not reported
BEV+TRC 105 (1 RCT, 49 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention leads to higher BEV+TRC 105 (1 RCT, 49 participants) (high certainty).
1 finding from 1 review
Intervention not reported
Outcomes (5 RCTs, 1024 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
1 finding from 1 review
Intervention not reported
BEV(8 RCTs; 498 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
1 finding from 1 review
Intervention not reported
FOM (1 RCT, 32 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in FOM (1 RCT, 32 participants); GRADE not reported.
1 finding from 1 review
Intervention not reported
BEV+HSPPC96 1 RCTs; 53 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in BEV+HSPPC96 1 RCTs; 53 participants) (low certainty).
1 finding from 1 review
Intervention not reported
BEV+ONA(1 RCT; 64 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in BEV+ONA(1 RCT; 64 participants) (low certainty).
1 finding from 1 review
Intervention not reported
BEV+CAB (1 RCT; 58 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in BEV+CAB (1 RCT; 58 participants) (low certainty).
1 finding from 1 review
Intervention not reported
BEV+DAS (2 RCTs, 83 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in BEV+DAS (2 RCTs, 83 participants) (high certainty).
1 finding from 1 review